Viking Therapeutics Inc VKTX introduced that new medical information from the corporate’s VK2735 weight problems program had been highlighted in two poster shows at ObesityWeek 2024.
Viking is evaluating each subcutaneous and oral formulations of VK2735 in medical trials.
Highlights from one poster presentation embrace new information from the Section 1 a number of ascending dose (MAD) trial of an oral pill formulation of VK2735 dosed every day for 28 days, together with outcomes for the research’s 60 mg, 80 mg, and 100 mg every day therapy cohorts.
Cohorts receiving VK2735 demonstrated dose-dependent reductions in imply physique weight from baseline, ranging as much as 8.2%.
Cohorts receiving VK2735 additionally demonstrated reductions in imply physique weight relative to placebo, ranging as much as 6.8%.
At follow-up visits by Day 57, persistent weight reduction results had been noticed, ranging as much as 8.3% from baseline 4 weeks after the final dose of VK2735 was administered.
An exploratory evaluation of the proportion of topics attaining no less than 5% weight reduction after 28 days demonstrated that as much as 100% of VK2735-treated topics achieved ≥5% weight reduction, in contrast with 0% for placebo.
A second poster presentation highlights follow-up outcomes from the corporate’s Section 2 VENTURE trial of VK2735.
As beforehand reported, sufferers receiving weekly doses of VK2735 demonstrated statistically important reductions in imply physique weight after 13 weeks, ranging as much as 14.7% from baseline.
Statistically important variations in comparison with baseline and placebo had been noticed for all doses beginning at Week One and persevering with all through the 13-week therapy interval.
Reductions in physique weight had been progressive all through the research, with no plateau noticed for weight reduction at 13 weeks. As well as, as much as 88% of sufferers in VK2735 therapy teams achieved ≥10% weight reduction, in contrast with 4% for placebo.
The outcomes additionally confirmed that every one cohorts receiving VK2735 maintained most of their weight reduction 4 weeks after receiving the ultimate dose of VK2735 within the research.
An exploratory evaluation of adjustments in diabetes standing was additionally carried out, demonstrating that therapy with VK2735 elevated the percentages of sufferers with prediabetic standing at baseline shifting to normoglycemic (non-diabetic) standing over the 13-week therapy interval.
Equally, the proportion of sufferers with regular glycemic standing at baseline transitioning to prediabetic standing favored VK2735, with roughly 31% of placebo sufferers transitioning to prediabetic standing, in contrast with 2% amongst sufferers receiving VK2735.
Oral VK2735 continued to display encouraging security and tolerability following 28 days of once-daily dosing at doses as much as and together with 100 mg.
Worth Motion: VKTX inventory is up 5.65% at $77.00 through the premarket session eventually test Monday.
Picture through Shutterstock
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
